Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial

Désirée van der Heijde, Atul Deodhar, Jürgen Braun, Michael Mack, Benjamin Hsu, Timothy A. Gathany, Robert D. Inman, Chenglong Han and The GO-RAISE investigators
The Journal of Rheumatology June 2014, 41 (6) 1095-1103; DOI: https://doi.org/10.3899/jrheum.131003
Désirée van der Heijde
From the Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands; Oregon Health and Science University, Portland, Oregon, USA; Rheumazentrum Ruhrgebiet, Herne, Germany; Biostatistics and Immunology, Janssen Research & Development LLC, Spring House; Janssen Global Services, Malvern, Pennsylvania, USA; Department of Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: d.vanderheijde@kpnplanet.nl
Atul Deodhar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jürgen Braun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Mack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Hsu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy A. Gathany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert D. Inman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chenglong Han
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To evaluate the effects of golimumab therapy on achieving inactive disease or major improvement, as assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS), and improvements in health-related quality of life (HRQOL) and productivity through 2 years in patients with AS.

Methods. In the phase III GO-RAISE trial, 356 patients were randomized to placebo with crossover to golimumab 50 mg at Week 24 (n = 78), golimumab 50 mg (n = 138), or golimumab 100 mg (n = 140) at baseline and every 4 weeks. The proportions of patients with ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score < 1.3) were determined. HRQOL was assessed using the 36-item Medical Outcomes Study Short Form-36 physical/mental component summary (SF-36 PCS/MCS) scores (normal score ≥ 50). The effect of disease on productivity was assessed by visual analog scale (0–10). Regression analyses on the association of disease activity and HRQOL were performed. The final assessment was at Week 104.

Results. Significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease at weeks 14 and 24 versus placebo. Through Week 104, patients who achieved ASDAS inactive disease or major improvement had significantly greater improvements in SF-36 PCS and MCS scores and productivity than did patients not meeting these targets. Among all patients, achieving ASDAS inactive disease at weeks 52 and 104 was associated with normalized SF-36 PCS/MCS scores and significant improvements in work productivity.

Conclusion. Greater proportions of golimumab-treated patients achieved ASDAS major improvement or inactive disease and improved HRQOL versus placebo. Achieving an inactive disease state by ASDAS criteria (< 1.3) was associated with normalized HRQOL through 2 years.

Key Indexing Terms:
  • GOLIMUMAB
  • ANKYLOSING SPONDYLITIS
  • HEALTH-RELATED QUALITY OF LIFE
  • PRODUCTIVITY
  • ASDAS

Ankylosing spondylitis (AS) is a chronic inflammatory disease, primarily affecting the spine and sacroiliac joints. Uncontrolled systemic inflammation in patients with AS is thought to precipitate extraarticular manifestations, including eye, skin, bone, and bowel disease1. AS typically presents in the third decade of life, thus disrupting patients’ work productivity2,3,4,5 and quality of life6,7,8 during their prime working years. Treatment with therapies targeting tumor necrosis factor (TNF) has been shown to improve health-related quality of life (HRQOL) in patients with AS9,10,11.

Disease activity in patients with AS has typically been evaluated with a variety of assessments that separately measure the patient’s assessment of disease, the physician’s assessment of disease, acute-phase reactants, and joint changes visible by MRI12. The composite Bath AS Disease Activity Index13 is a commonly used activity measure in clinical trials; however, it is limited to only patient-reported outcomes. The Bath AS Functional Index is a validated measure for assessing physical function in patients with AS. A 20% improvement in the Assessment of SpondyloArthritis international Society (ASAS)14 criteria is also a commonly used endpoint in clinical trials, but it relies on measuring a change from a reference baseline status and cannot be used to determine disease state at a given timepoint. The ASAS 5/6 improvement criteria includes C-reactive protein (CRP) and performs well in anti-TNF trials, but like the ASAS20 response15, it is limited to measuring improvements over time. Recently, ASAS has developed a well-balanced AS Disease Activity Score (ASDAS) that incorporates both patient-reported outcomes and either CRP or erythrocyte sedimentation rate (ESR)16. The validated ASDAS can be used to assess disease activity as a continuous measure or as discrete levels as well as measuring improvement following treatment17.

In the GO-RAISE trial, the safety and efficacy of golimumab, a human monoclonal anti-TNF antibody, was evaluated in adult patients with active AS. Patients treated with golimumab 50 mg or 100 mg had significantly greater improvements in the signs and symptoms of AS and HRQOL compared with those who received placebo18, and response to golimumab treatment was maintained for up to 2 years as reported19. In a limited posthoc analysis using the ASDAS, significantly greater proportions of patients treated with golimumab 50 mg or 100 mg had an ASDAS < 1.1 or < 2.1 at Week 24 when compared with those who received placebo; response rates were generally similar among treatment groups at weeks 52 and 104, after placebo patients had been receiving golimumab for several months19. We now report the findings of additional posthoc analyses of the GO-RAISE trial evaluating ASDAS inactive disease and major clinical response and the association of these outcomes with changes in HRQOL and the effect of disease on productivity.

MATERIALS AND METHODS

Patients and study design

The detailed patient eligibility criteria and study design of the GO-RAISE trial have been reported18. Briefly, adult patients with active AS were randomly assigned to receive subcutaneous injections of placebo (Group 1), golimumab 50 mg (Group 2), or golimumab 100 mg (Group 3) at baseline and every 4 weeks. At Week 16, patients who had < 20% improvement in total back pain and morning stiffness entered blinded early escape, such that patients in Group 1 switched to golimumab 50 mg injections, and patients in Group 2 had their golimumab dose increased from 50 mg to 100 mg. No treatment adjustments were permitted for patients in Group 3 regardless of their early escape status. At Week 24, all patients who were still receiving placebo crossed over to golimumab 50 mg. No additional changes in treatment were permitted after Week 24, and all golimumab injections continued to be administered every 4 weeks through Week 100; the final visit included in our analysis was at Week 104.

The protocol was approved by the institutional review board or ethics committee at each site. All patients gave written informed consent before any study-related procedures were performed.

Assessments

In this posthoc analysis, disease activity was evaluated using the composite ASDAS, which was developed after the GO-RAISE trial was initiated. The ASDAS incorporates measures of back pain, duration of morning stiffness, patient global assessment, peripheral pain/swelling, and CRP17,20. There is no upper limit to the ASDAS, and a higher score indicates more severe disease17, with the following cutpoints indicating different levels of disease activity: < 1.3 = inactive disease, 1.3 to < 2.1 = moderate disease, 2.1 to 3.5 = high disease activity, and > 3.5 = very active disease20. ASDAS major improvement was defined as an improvement ≥ 2.0 from baseline20.

Patient HRQOL was assessed using the physical component summary (PCS) and mental component summary (MCS) scores of the 36-item Medical Outcomes Study Short Form-36 (SF-36)21. The effect of disease on productivity at work, school, or home was evaluated using a visual analog scale (VAS, 0–10 cm). Employability was self-reported and defined as currently working or able to work if a job is available.

Statistical analysis

Descriptive statistics are reported by randomized treatment group. ASDAS scores were assessed at weeks 0, 14, 24, 52, and 104; the proportions of patients in each treatment group achieving ASDAS major improvement or inactive disease were also determined through Week 104. Mean changes from baseline in SF-36 PCS and MCS scores, and the proportions of patients with normal PCS and MCS scores (≥ 50) or a minimal clinically important difference (MCID; improvement ≥ 5 units) were determined at weeks 14, 24, 52, and 104. Improvements from baseline in the effect of disease on productivity were determined at weeks 16, 24, 52, and 104; employment status for patients who were unemployable at baseline because of AS was assessed at weeks 24, 52, and 104. Through Week 24, differences between Group 1 and Groups 2 and 3 were evaluated using an ANOVA on the van der Waerden normal scores for continuous variables and chi-square test for dichotomous variables. Statistical comparisons among the treatment groups were not performed beyond Week 24 because all patients were receiving golimumab.

For patients in Group 1 and Group 2 who met the early escape criteria at Week 16, Week 16 values were carried forward to Week 24; however, if the Week 16 value was missing, the values at Week 24 were set to missing. Mean improvements in SF-36 PCS and MCS scores and the proportions of patients with normal PCS and MCS scores were compared between patients with ASDAS major improvement or inactive disease and those who were nonresponders. Relative risks (RR) for achieving normal SF-36 PCS and MCS scores among patients who achieved ASDAS inactive disease were estimated using log-binomial regression models that adjusted for treatment group and age (both PCS and MCS analyses), as well as baseline SF-36 MCS score (MCS analysis only).

RESULTS

Baseline characteristics

A total of 356 patients were randomly assigned to Group 1 (placebo, n = 78), Group 2 (golimumab 50 mg, n = 138), or Group 3 (golimumab 100 mg, n = 140). Demographic and baseline disease characteristics were generally well-balanced among the treatment groups and have been detailed previously18. The population was predominantly male and exhibited significant disease activity at baseline (Table 1). The physical effect of AS on patients’ HRQOL was evident in the SF-36 PCS scores (means: 29.2–30.7 across treatment groups).

View this table:
  • View inline
  • View popup
Table 1.

Baseline demographic and disease characteristics. Data are presented as mean (SD) unless otherwise noted.

Clinical response

Mean ASDAS scores were similar across the treatment groups at baseline (Table 1). During the 24-week placebo-controlled period, improvements in ASDAS were significantly greater in Groups 2 and 3 than in Group 1 at both weeks 14 and 24 (Table 2). Significantly greater proportions of patients in Groups 2 and 3 achieved ASDAS major improvement when compared with Group 1 at both Week 14 (37.0% and 38.5% vs 5.1%; p < 0.001) and Week 24 (39.4% and 39.0% vs 4.2%; p < 0.001; Figure 1). Likewise, significantly greater proportions of patients in Groups 2 and 3 had ASDAS inactive disease at weeks 14 and 24 (Figure 1). Following placebo crossover to golimumab 50 mg at Week 16 (early escape) or 24 (crossover), mean improvements from baseline in ASDAS scores at weeks 52 and 104 were similar across all 3 treatment groups (Table 2).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Proportions of patients with ASDAS major improvement (A) or inactive disease (B) at weeks 14 and 24. *p < 0.001. ASDAS: Ankylosing Spondylitis Disease Activity Score.

View this table:
  • View inline
  • View popup
Table 2.

Improvements in ASDAS, health-related quality of life, and productivity through Week 104a. Data presented as n (%) or mean ± SD.

HRQOL and productivity

Previously, median improvements in SF-36 PCS and MCS scores in the randomized treatment groups through Week 24 and mean improvements at weeks 52, 76, and 104 with patients classified according to early escape status were reported18,19. Here we report mean improvements in SF-36 PCS and MCS scores by randomized treatment group (Table 2). Consistent with earlier reports, patients in Groups 2 and 3 had greater mean improvements in SF-36 PCS and MCS scores at weeks 14 and 24 than did patients in Group 1, and mean improvements at weeks 52 and 104 were similar among the treatment groups (Table 2). Additionally, the proportions of patients who achieved a normal SF-36 PCS score (≥ 50) or an MCID in SF-36 PCS were significantly greater in Groups 2 and 3 than in Group 1 at weeks 14 and 24 (Table 2). The proportions of patients with a normal MCS score at weeks 14 and 24 were not significantly different among the treatment groups, ranging from 46.2% to 48.9% and from 49.3% to 52.6%, respectively. At weeks 52 and 104, when all patients had been receiving golimumab for several months, the proportions of patients with normal SF-36 PCS or MCS scores or with an MCID in score were similar among all treatment groups (Table 2).

Mean improvements in the effect of disease on productivity were significantly greater in Groups 2 and 3 than in Group 1 at weeks 16 and 24 (Table 2). Improvements in productivity were similar among the treatment groups at weeks 52 and 104 and ranged from 3.4 to 3.7 and from 3.8 to 4.1, respectively. Among patients who reported that they were unemployable at baseline and had not retired before Week 24, 34.3% (12/35) of those in Groups 2 and 3 combined and 20.0% (2/10) in Group 1 regained employability at Week 24; however, this numerical difference was not statistically significant. At weeks 52 and 104, 17/36 (47.2%) and 19/28 (67.9%) of patients, respectively, who were unemployable at baseline because of AS had regained employability.

Among all patients, those who had ASDAS major improvement or inactive disease at weeks 14, 24, 52, and 104 had significantly greater mean improvements in SF-36 PCS scores than did patients who were nonresponders (Figure 2A–D). ASDAS responders also had greater improvements in SF-36 MCS scores, although these differences were not always statistically significant (Figure 2A–D). In addition, greater proportions of patients with ASDAS major improvement or inactive disease had normal SF-36 PCS scores (≥ 50) when compared with nonresponders (Figure 2E–H). Overall, greater proportions of ASDAS responders versus nonresponders had normal SF-36 MCS scores (≥ 50); however, this difference was not always statistically significant (Figure 2E–H). Regression analyses showed that achieving ASDAS inactive disease at weeks 52 and 104 was significantly associated with having a normal SF-36 PCS score at weeks 52 and 104 and a normal SF-36 MCS score at Week 104 (Table 3).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Mean improvements in SF-36 PCS and MCS scores (A–D) and the proportions of patients who achieved a normal SF-36 PCS and MCS score (≥ 50; E–H) among patients who achieved ASDAS major improvement or inactive disease. All patients who were randomized to placebo switched to golimumab at Week 16 (early escape) or Week 24 (prespecified crossover). *p < 0.05, ** p < 0.01, *** p < 0.001. ASDAS: Ankylosing Spondylitis Disease Activity Score; SF-36 PCS/MCS: 36-item Medical Outcomes Study Short Form-36 physical/mental component summary.

View this table:
  • View inline
  • View popup
Table 3.

Relative risk for achieving normal SF-36 PCS and MCS scores among patients who achieved ASDAS inactive disease at weeks 52 and 104a.

Patients with ASDAS major improvement or inactive disease had a significantly greater median percent improvement in productivity than did nonresponders at weeks 16, 24, 52, and 104 (Figure 3). Among patients who were unemployable at baseline owing to AS and had ASDAS data available, 15 achieved ASDAS major improvement at Week 52, and 11 of these patients (73.3%) regained employability. In addition, 7 patients who were unemployable at baseline achieved ASDAS inactive disease at Week 52, and 6 of these patients (85.7%) regained employability. At Week 104, 13 of the 14 (92.9%) patients who had major improvement regained employability, and all 7 patients who achieved inactive disease regained employability.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Median percent improvement in productivity among patients who achieved ASDAS major improvement (A) or inactive disease (B). All patients who were randomized to placebo switched to golimumab at Week 16 (early escape) or Week 24 (prespecified crossover). * p < 0.001. ASDAS: Ankylosing Spondylitis Disease Activity Score.

DISCUSSION

Historically, disease activity in AS has been measured using a combination of tools that separately evaluated the patient’s assessment of disease, the physician’s assessment of disease, and acute-phase reactants. Many of these tools are limited to 1 aspect of disease activity or allow for only the physician’s or the patient’s assessment. The ASAS20 response, a commonly used study endpoint, is useful in determining improvement from baseline in signs and symptoms, but cannot measure absolute disease activity at a given timepoint and does not include an objective measure of disease activity14,15.

The ASDAS is the first disease activity index for AS that includes both patient-reported outcomes and acute-phase reactants, which physicians may emphasize over subjective measures22. It has been shown to correlate well with both the patient and physician global assessments17. The burden to patients and physicians is low in that it is easy to administer and calculate23. While the ASDAS is the newest disease activity measure for AS, analyses have shown that this index reliably discriminates between disease states and is sensitive to changes in disease activity following treatment17.

In a previous report of the primary 2-year findings of the GO-RAISE trial, golimumab was shown to be effective in reducing the signs and symptoms of AS in adult patients through 2 years of treatment19. Limited ASDAS results (proportions of patients with ASDAS < 1.1 or < 2.1) were reported in the previous analysis19 and are consistent with the findings of the more detailed ASDAS analysis presented here. In the current analysis, patients treated with golimumab 50 mg and 100 mg had significantly greater improvements in ASDAS scores than did patients who received placebo, and significantly greater proportions of golimumab-treated patients achieved ASDAS major improvement (improvement ≥ 2.0) or inactive disease (score < 1.3) at weeks 14 and 24 when compared with those who received placebo.

Improvements in HRQOL and health economic measures were similar for the 2 golimumab doses studied (50 mg and 100 mg) and were consistent with improvements seen with other anti-TNF agents24,25,26. Consistent with earlier reports of the GO-RAISE trial18,19, golimumab-treated patients had significantly greater mean improvements in SF-36 PCS scores through Week 24; mean improvements in SF-36 MCS scores were not as pronounced, likely owing to the near-normal mean MCS scores at baseline. Greater proportions of golimumab-treated patients achieved normal HRQOL (SF-36 PCS/MCS scores) or a clinically significant improvement in HRQOL when compared with those who received placebo. Through Week 24, golimumab-treated patients had significantly greater improvements in productivity versus placebo. In addition, a trend toward greater employability at Week 24 was observed.

In general, patients who achieved ASDAS major improvement or inactive disease had significantly greater improvements in HRQOL through Week 104 than did ASDAS nonresponders. Further, achievement of ASDAS inactive disease was significantly associated with normal HRQOL. It should be noted that instead of using OR, we calculated RR, which are more appropriate in this situation but often yield lower values27. ASDAS responders (major improvement or inactive disease) also experienced greater improvements in the effect of disease on productivity and were more likely to have an improvement in their employability status compared with nonresponders.

Recently, efforts have been made to define treatment targets for patients with spondyloarthritis, including AS, with the recommendation that, whenever possible, inactive disease should be a major treatment target for patients with AS28. In our analysis of the GO-RAISE trial, patients who achieved ASDAS inactive disease appeared to have greater improvements in HRQOL outcomes than did patients who achieved ASDAS major improvement, although statistical comparisons were not performed. These results together with the association of inactive disease with normalized HRQOL support the recommendation of inactive disease as a treatment target in AS28.

It should be noted that the ASDAS can be calculated using either CRP or ESR; however, the ASDAS using CRP is the preferred method given that CRP measurements can be accurately performed with stored serum samples and using standardized assays in a central laboratory17. ESR can be used as an alternative when CRP levels are not available, but it is not recommended to use the resulting scores interchangeably in the same analysis or for the same patient17. ESR measurements were not collected during the GO-RAISE study; therefore, we could not evaluate the performance of ASDAS using ESR with regards to HRQOL and employment outcomes.

This analysis of the GO-RAISE trial is primarily limited by the posthoc nature of our study. The determination of ASDAS results was not prespecified in the protocol because the ASDAS did not exist when the trial began, and the GO-RAISE trial was not specifically designed to evaluate the relationship between HRQOL and health economic outcomes with changes in ASDAS scores.

Previous analyses have demonstrated that the ASDAS can discriminate between AS disease activity states as well as or better than existing measures17. In the current analysis, patients who achieved ASDAS major improvement or inactive disease consistently had greater improvements in SF-36 PCS and MCS scores and productivity when compared with those who did not achieve major improvement or inactive disease. Also, achievement of ASDAS inactive disease was significantly associated with normalized SF-36 PCS and MCS scores, which supports the recent recommendation that achieving inactive disease should be a major treatment goal in patients with AS28. These findings indicate that, in addition to discriminating clinical disease activity, ASDAS response is consistent with improvements in various HRQOL and health economic outcomes.

Acknowledgment

The authors thank Rebecca E. Clemente, PhD, and Mary Whitman, PhD, of Janssen Biotech Services LLC for writing and editorial support.

Footnotes

  • Supported by Janssen Research & Development LLC and Merck/Schering-Plough. Authors MM, BH, TAG, and CH are employees of the study sponsor and own stock in Johnson & Johnson, of which Janssen Research & Development LLC and Janssen Global Services LLC are subsidiaries. DvdH has received consulting fees and/or research grants from AbbVie, Amgen, AstraZeneca, Augurex, BMS, Celgene, Chugai, Covagen, Daiichi, Eli-Lilly, GSK, Janssen Biologics, Merck, Novartis, Novo-Nordisk, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, and Vertex and is director of imaging at Rheumatology bv. AD has received payments for educational lectures, teleconferences and serving on advisory boards for Janssen, a company that may have a commercial interest in the results of this research. JB has received honoraria for talks, advisory boards, and grants for studies from Janssen Research & Development LLC, Amgen, Abbott, BMS, Celltrion, Novartis, Pfizer (Wyeth), MSD (Schering-Plough), Roche, Sanofi-Aventis, and UCB. RDI has received consulting fees from Merck, Schering-Plough, Abbott, Amgen, and Sanofi-Aventis.

  • Accepted for publication February 12, 2014.

REFERENCES

  1. 1.↵
    1. El Maghraoui A
    . Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011;22:554–60.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Boonen A
    . Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S23–6.
    OpenUrlPubMed
  3. 3.↵
    1. Boonen A,
    2. Chorus A,
    3. Miedema H,
    4. van der Heijde D,
    5. van der Tempel H,
    6. van der Linden S
    . Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353–8.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Boonen A,
    2. van der Heijde D,
    3. Landewe R,
    4. Spoorenberg A,
    5. Schouten H,
    6. Rutten-van Molken M,
    7. et al.
    Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429–37.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. van der Burg LR,
    2. Ter Wee MM,
    3. Boonen A
    . Effect of biological therapy on work participation in patients with ankylosing spondylitis: a systematic review. Ann Rheum Dis 2012;71:1924–33.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Bostan EE,
    2. Borman P,
    3. Bodur H,
    4. Barca N
    . Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 2003;23:121–6.
    OpenUrlPubMed
  7. 7.↵
    1. Dagfinrud H,
    2. Mengshoel AM,
    3. Hagen KB,
    4. Loge JH,
    5. Kvien TK
    . Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 2004;63:1605–10.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ward MM
    . Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 1998;24:815–27.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Boonen A,
    2. Patel V,
    3. Traina S,
    4. Chiou CF,
    5. Maetzel A,
    6. Tsuji W
    . Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 2008;35:662–7.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Davis JC Jr.,
    2. Revicki D,
    3. van der Heijde DM,
    4. Rentz AM,
    5. Wong RL,
    6. Kupper H,
    7. et al.
    Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 2007;57:1050–7.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Han C,
    2. Smolen JS,
    3. Kavanaugh A,
    4. van der Heijde D,
    5. Braun J,
    6. Westhovens R,
    7. et al.
    The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007;9:R103.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Pedersen SJ,
    2. Sorensen IJ,
    3. Hermann KG,
    4. Madsen OR,
    5. Tvede N,
    6. Hansen MS,
    7. et al.
    Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065–71.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Garrett S,
    2. Jenkinson T,
    3. Kennedy LG,
    4. Whitelock H,
    5. Gaisford P,
    6. Calin A
    . A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
    OpenUrlPubMed
  14. 14.↵
    1. Anderson JJ,
    2. Baron G,
    3. van der Heijde D,
    4. Felson DT,
    5. Dougados M
    . Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Brandt J,
    2. Listing J,
    3. Sieper J,
    4. Rudwaleit M,
    5. van der Heijde D,
    6. Braun J
    . Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438–44.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Lukas C,
    2. Landewe R,
    3. Sieper J,
    4. Dougados M,
    5. Davis J,
    6. Braun J,
    7. et al.
    Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. van der Heijde D,
    2. Lie E,
    3. Kvien TK,
    4. Sieper J,
    5. Van den Bosch F,
    6. Listing J,
    7. et al.
    ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811–8.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Inman RD,
    2. Davis JC Jr.,
    3. van der Heijde D,
    4. Diekman L,
    5. Sieper J,
    6. Kim SI,
    7. et al.
    Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402–12.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Braun J,
    2. Deodhar A,
    3. Inman RD,
    4. van der Heijde D,
    5. Mack M,
    6. Xu S,
    7. et al.
    Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2011;71:661–7.
    OpenUrlPubMed
  20. 20.↵
    1. Machado P,
    2. Landewe R,
    3. Lie E,
    4. Kvien TK,
    5. Braun J,
    6. Baker D,
    7. et al.
    Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Ware JE Jr.,
    2. Sherbourne CD
    . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Spoorenberg A,
    2. van Tubergen A,
    3. Landewe R,
    4. Dougados M,
    5. van der Linden S,
    6. Mielants H,
    7. et al.
    Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 2005;44:789–95.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Zochling J
    . Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S47–58.
    OpenUrlCrossRef
  24. 24.↵
    1. Braun J,
    2. McHugh N,
    3. Singh A,
    4. Wajdula JS,
    5. Sato R
    . Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 2007;46:999–1004.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. van der Heijde D,
    2. Dijkmans B,
    3. Geusens P,
    4. Sieper J,
    5. DeWoody K,
    6. Williamson P,
    7. et al.
    Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582–91.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. van der Heijde DM,
    2. Revicki DA,
    3. Gooch KL,
    4. Wong RL,
    5. Kupper H,
    6. Harnam N,
    7. et al.
    Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. McNutt LA,
    2. Wu C,
    3. Xue X,
    4. Hafner JP
    . Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003;157:940–3.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Smolen JS,
    2. Braun J,
    3. Dougados M,
    4. Emery P,
    5. Fitzgerald O,
    6. Helliwell P,
    7. et al.
    Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 41, Issue 6
1 Jun 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Désirée van der Heijde, Atul Deodhar, Jürgen Braun, Michael Mack, Benjamin Hsu, Timothy A. Gathany, Robert D. Inman, Chenglong Han, The GO-RAISE investigators
The Journal of Rheumatology Jun 2014, 41 (6) 1095-1103; DOI: 10.3899/jrheum.131003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Effect of Golimumab Therapy on Disease Activity and Health-related Quality of Life in Patients with Ankylosing Spondylitis: 2-year Results of the GO-RAISE Trial
Désirée van der Heijde, Atul Deodhar, Jürgen Braun, Michael Mack, Benjamin Hsu, Timothy A. Gathany, Robert D. Inman, Chenglong Han, The GO-RAISE investigators
The Journal of Rheumatology Jun 2014, 41 (6) 1095-1103; DOI: 10.3899/jrheum.131003
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

GOLIMUMAB
ANKYLOSING SPONDYLITIS
HEALTH-RELATED QUALITY OF LIFE
PRODUCTIVITY
ASDAS

Related Articles

Cited By...

More in this TOC Section

  • Vasculitis: What Have We Learned in the Last 50 Years?
  • Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies
  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Show more Article

Similar Articles

Keywords

  • GOLIMUMAB
  • ankylosing spondylitis
  • health-related quality of life
  • PRODUCTIVITY
  • ASDAS

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire